Almost one decade ago, etoposide, doxorubicin, cisplatin and mitotane (EDP-M) has been
established as first-line systemic therapy of metastatic adrenocortical carcinoma (ACC) …

Adrenocortical carcinoma (ACC) is an aggressive cancer characterized by poor survival.
Apart from radical surgery, there is a limited range of therapeutic options and mitotane …

Adrenocortical carcinoma (ACC) is a rare and in most cases steroid hormone-producing
tumor with variable prognosis. The purpose of these guidelines is to provide clinicians with …

Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with an annual incidence
of~ 1 case per million population. Differentiating between ACC and benign adrenocortical …

Mitotane is used as a post-operative adjuvant treatment for patients with adrenocortical
carcinoma. Monitoring of plasma mitotane concentrations is recommended, but we do not …

A relevant issue on the treatment of adrenocortical carcinoma (ACC) concerns the optimal
duration of adjuvant mitotane treatment. We tried to address this question, assessing …

Adrenocortical carcinoma (ACC) is a heterogeneous malignancy related to poor prognosis
and limited treatment options. The orphan drug mitotane (MT) is still a cornerstone in ACC …

Introduction: Adrenocortical carcinoma (ACC) is a rare tumor characterized by poor
prognosis in most cases. Moreover, in most cases ACC produces an excess of adrenal …

Objective: To define the prognostic factors associated with overall survival (OS) and cancer-
specific survival (CSS) for adrenocortical carcinoma (ACC). Patients and Methods: We used …

Adrenocortical carcinoma (ACC) is a rare disease with a poor prognosis. The presence of a
mass syndrome or signs of hormonal hypersecretion often lead to its discovery, but more …